SUMMARY The systematic screening of 253 children with transfusion-dependent homozygous P-thalassaemia revealed a high incidence of hepatitis B virus markers. The highest frequencies of hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen (anti-HBc) were found in the group of patients with the smallest number of transfusions, while the highest frequency of antibody to hepatitis B surface antigen (anti-HBs) was detected in the patients who had had the largest number of transfusions. Follow-up of these patients showed (a) a high incidence of acute hepatitis B, which was mainly subclinical; (b) normal hepatitis B surface antigen clearance and normal antibody to hepatitis B surface development; and (c) a high frequency of increased transaminase values for over six months. In all the subjects with persistently high transaminase, histological examination revealed chronic persistent hepatitis or chronic active hepatitis. Apart from two cases of chronic active hepatitis with no B virus markers, and two cases of chronic persistent hepatitis with HBsAg and anti-HBc in the serum, all these subjects were anti-HBs positive but HBsAg and anti-HBc negative.
Chronic hepatitis occurs very frequently in children with transfusion-dependent thalassaemia in the Mediterranean area, including Sardinia.1-6 Viral agents implicated in transfusional hepatitis3 6 7 and iron overload,8 resulting from the high transfusion regimen are considered to be the main causes. Among the hepatitis viruses, a predominant role is ascribed to hepatitis B virus (HBV), while little, if any role, has been given to the A virus.7
In the United States, it has recently been shown that the non-A, non-B virus(es) seem to cause transfusional hepatitis even more frequently than HBV.9 However, there are no data on the incidence of this viral infection in the Mediterranean area.
To elucidate the role of HBV in the development of chronic liver disease in 253 children with transfusion-dependent thalassaemia major, we carried out: (a) a survey of the prevalence of HBV markers; (b) a two-year follow-up of HBV markers and liver function tests; and (c) liver biopsy studies in patients with persistently increased transaminase levels.
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INCIDENCE AND FOLLOW-UP OF HBV MARKERS
The prevalence of HBV markers in the 253 regularly transfused thalassaemia major patients is shown in Table 1 . The patients are divided into three groups according to the units of blood received. The highest prevalence of HBsAg was found in the group of patients with the smallest number of transfusions, while the highest prevalence of anti-HBs is in those who had the largest number of blood transfusions. The behaviour of anti-HBc was similar to that of HBsAg. Anti-HBc was found in seven subjects: in four it was associated with HBsAg and in three it was the only viral marker detected.
On follow-up of the four patients with both antiHBc and HBsAg, two, persistently positive for these markers, developed chronic persistent hepatitis (CPH), and two had clearance of both markers in 18 and 24 months, respectively, followed by the appearance of anti-HBs. The three cases showing anti-HBc as the only marker had clearance of this marker in six to eight months and developed anti-HBs positivity.
The HBsAg positive cases cleared in two to four months and developed anti-HBs, which was present throughout follow-up. Those with only anti-HBs positivity had persistence of this antibody for the two-year follow-up period.
After 12 months' follow-up one subject with persistent anti-HBs positivity developed both HBsAg and anti-HBc, persisting for six months. The anti-HBs positivity in this subject persisted for the whole two years. One month after the appearance of HBsAg and anti-HBc, clinical acute hepatitis with SGPT > 250 mU/ml developed. Another patient with persistent anti-HBs positivity developed HBsAg and anti-HBc while anti-HBs disappeared. During the six-month follow-up, HBsAg and antiHBc remained positive while anti-HBs was persistently absent. This subject showed no clinical or biochemical manifestations of liver disease and, particularly, no signs of immunocomplex disorders. Unfortunately, HBsAg subtype characterisation was not performed.
HBV MARKERS IN ACUTE CLINICAL OR SUBCLINICAL HEPATITIS
The monthly determination of HBV markers in a randomly selected group of subjects enabled us to follow up the development of these markers in 35 Anti-HBs began to be recognisable four months after the clinical and/or biochemical onset of hepatitis; the incidence increased progressively to 990% of cases in the seventh month. Successively it was present in almost all patients during the two-year observation period.
INCREASE IN SERUM TRANSAMINASES
As can be seen in Table 2 , the monthly serum transaminase determination showed very high SGPT values (>250 mU/ml) in 35 patients, who also had clinical signs of acute hepatitis; in 34 of them, HBsAg and/or anti-HBc, previously absent, was detected.
One hundred and fifty-six patients had serum transaminases ranging from 40 to 250 U; 135 of these showed the presence of at least one of the viral markers. None of these patients had clinical signs of acute hepatitis (Table 2 ). Serum transaminases of less than 40 were seen in 62 patients with no viral markers in the serum.
The incidence of raised transaminase levels for a shorter or longer period of time was higher in HBV positive (approx 30 %) than in HBV negative (approx 9%) subjects (Table 3) . 
